Calidi Biotherapeutics

CLDI · NYSE American

$0.77−$0.0134 (−1.71%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.7834

CLDI analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Sep 19, 2024

Bull case

Calidi Biotherapeutics Inc. is positioned to leverage its innovative stem cell-based platform, which enhances the delivery and efficacy of oncolytic viruses in cancer treatment, potentially leading to improved therapeutic outcomes and safety profiles. The company’s promising preclinical results indicate significant anti-tumor activity and tumor growth inhibition across various tumor types, suggesting the potential for a strong clinical pipeline. Furthermore, as Calidi advances its developmental programs, the projected narrowing of valuation discrepancies with direct peers highlights a favorable market position that could enhance investor interest.

Bear case

Calidi Biotherapeutics faces significant risks that may negatively impact its financial outlook, including the potential for negative preliminary clinical trial results and the inability to advance key therapeutic candidates into pivotal clinical stages. The company's historical lack of profitability, coupled with the challenges of systemic delivery of oncolytic viruses and the high likelihood of operational hurdles in penetrating target markets, raises concerns about future revenue generation. Furthermore, the reliance on ongoing equity financing introduces dilution risk, further complicating the company's path toward achieving sustainable financial success.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.